- ENDURANCE-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With HCV Genotype 3 Infection; Foster, G et al. Poster Presentation, Clinical trials in progress: Thursday, April 14 at 08:00am-18:00pm CEST; #THU-482
Catalyst
Slingshot members are tracking this event:
Enanta Pharmaceuticals (ENTA) Enrolls Patients in Phase 3 Study of ABT-493 and ABT-530 in treating Pan-Genotypic Hepatitis C
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ENTA |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 15, 2016
Occurred Source:
http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2157445
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Hepatitis C, Abt-493, Abt-530
